- Home
- PLX vs DBI Comparison
PLX vs DBI Comparison
Compare PLX & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- DBI
- Stock Information
- Founded
- PLX 1993
- DBI 1991
- Country
- PLX United States
- DBI United States
- Employees
- PLX N/A
- DBI N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- DBI Clothing/Shoe/Accessory Stores
- Sector
- PLX Health Care
- DBI Consumer Discretionary
- Exchange
- PLX Nasdaq
- DBI Nasdaq
- Market Cap
- PLX 122.6M
- DBI 136.7M
- IPO Year
- PLX 1998
- DBI 1991
- Fundamental
- Price
- PLX $1.37
- DBI $2.82
- Analyst Decision
- PLX Strong Buy
- DBI Hold
- Analyst Count
- PLX 1
- DBI 2
- Target Price
- PLX $15.00
- DBI $3.50
- AVG Volume (30 Days)
- PLX 1.3M
- DBI 1.7M
- Earning Date
- PLX 08-13-2025
- DBI 06-10-2025
- Dividend Yield
- PLX N/A
- DBI 7.12%
- EPS Growth
- PLX N/A
- DBI N/A
- EPS
- PLX 0.05
- DBI N/A
- Revenue
- PLX $59,764,000.00
- DBI $2,949,575,000.00
- Revenue This Year
- PLX $65.02
- DBI N/A
- Revenue Next Year
- PLX $57.34
- DBI $2.45
- P/E Ratio
- PLX $28.34
- DBI N/A
- Revenue Growth
- PLX 0.18
- DBI N/A
- 52 Week Low
- PLX $0.82
- DBI $2.18
- 52 Week High
- PLX $3.10
- DBI $8.45
- Technical
- Relative Strength Index (RSI)
- PLX 41.78
- DBI 56.50
- Support Level
- PLX $1.43
- DBI $2.37
- Resistance Level
- PLX $1.54
- DBI $3.20
- Average True Range (ATR)
- PLX 0.09
- DBI 0.20
- MACD
- PLX 0.01
- DBI 0.09
- Stochastic Oscillator
- PLX 5.77
- DBI 86.70
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.